159857-70-2
159857-70-2
Chemical Structure
MC-Val-Cit-Doxorubicin
Synonym(s): MC-Val-Cit-PAB-Doxorubicin
- CAS No.: 159857-70-2
- Formula:C56H67N7O19
- Molecular Weight:1142.17
IUPAC Name: 4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H-pyran-4-yl)carbamate
InChIKey: AYPRDRFYAQTVPD-GITVTGCLSA-N
SMILES: OC1=C2C(C(C3=C(OC)C=CC=C3C2=O)=O)=C(O)C([C@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC(OCC6=CC=C(C=C6)NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN7C(C=CC7=O)=O)=O)=O)=O)=O)=C1C[C@](O)(C4)C(CO)=O
Biological Activity: MC-Val-Cit-Doxorubicin (MC-Val-Cit-PAB-Doxorubicin) is drug-linker conjugate for ADC. The maleimide can conjugate with thiol containing molecules. Doxorubicin is an anthracycline antibiotic with antineoplastic activity
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MC-Val-Cit-Doxorubicin | 99.67% | MC-Val-Cit-Doxorubicin (MC-Val-Cit-PAB-Doxorubicin) is drug-linker conjugate for ADC. The maleimide can conjugate with thiol containing molecules. Doxorubicin is an anthracycline antibiotic with antineoplastic activity | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DTS-201 | DTS-201 (CPI-0004) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-PEG4-VC-PAB-DMEA-PNU-159682 | 97.53% | Mal-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 | Mal-Phe-C4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-Phe-C4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
vc-PAB-DMEA-PNU159682 | vc-PAB-DMEA-PNU159682 (compound I.47) can be used to synthesize the ADC molecule based on Sulfomaleimide-based Linker. vc-PAB-DMEA-PNU159682 has good serum stability. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Val-Cit-PABC-DOX | 95.06% | Val-Cit-PABC-DOX is an ε-poly-L-lysine-based drug conjugate, serving as a drug-linker conjugate for ADC. It is formed by conjugating Doxorubicin (HY-15142), an inhibitor of DNA topoisomerase I and topoisomerase II, with Val-Cit-PABC. Val-Cit-PABC-DOX relies on the self-cleavable PABC spacer to enable Cathepsin B-mediated linker cleavage and release of free Doxorubicin (HY-15142A). Val-Cit-PABC-DOX can be used in cancer-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-VC-PAB-DMEA-PNU-159682 | 99.36% | Mal-VC-PAB-DMEA-PNU-159682 (SET0568) is an antibody-drug conjugate (ADC) drug-linker conjugate. Mal-VC-PAB-DMEA-PNU-159682 is generated by conjugating the potent anti-topoisomerase II inhibitor PNU-159682 (HY-16700) to the lysosomally cleavable dipeptide Mc-VC-PAB, and exhibits strong antitumor activity. Mal-VC-PAB-DMEA-PNU-159682 can be used to synthesize CD22-targeting ADCs, such as Anti-CD22-NMS249 (HY-164761). Mal-VC-PAB-DMEA-PNU-159682 is also applicable to the research of non-Hodgkin's lymphoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-Val-Ala-amide-(3)PEA-PNU-159682 | Mal-Val-Ala-amide-(3)PEA-PNU-159682 is a Drug-Linker Conjugates for ADC, composes of ADC linker (Mal-Val-Ala-amide-(3)PEA) and ADC cytotoxin PNU-159682 (HY-16700), and has anti-tumor activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
EMC-AANL-DOX | EMC-AANL-DOX is a legumain-activated prodrug conjugate of Doxorubicin (DOX) (HY-15142A). EMC-AANL-DOX shows antitumor activity in mouse models of neuroblastoma (NB), breast cancer (4T1), fibrosarcoma (HT1080), and colorectal cancer liver metastases (CT26). EMC-AANL-DOX can be used for cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DTS-201 sodium | DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
